In the North American, non-Ashkenazic population, about 70% of CF chromosomes carry a 3-bp deletion, resulting in the loss of single phenylalanine residue at position 508 of the CFTR protein (SF508) (3) (4) (5) . About 50% of affected individuals are homozygous for the SF508 mutation; the remainder carry other mutations, either as homozygotes or compound heterozygotes. Several mutations have been found in exons 10 and 11, corresponding to the putative first nucleotide-binding fold. These include the missense mutation, G551D (6), and nonsense mutations, R553X (6) and G542X (7) . Mutations have been characterized in other functional domains of the CFTR gene as well, including N1303K, located in the second nucleotide-binding fold (8). At present, the combined efforts of many laboratories have characterized >60 different CF-causing mutations (9).
As this number has risen, hopes have declined for the generation of a simple, cost-effective clinical test applicable to general population screening for carrier status (9) .
Further complicating matters is the absence of a single widely accepted methodology for the detection of one or more of these mutations. If a mutation creates or destroys a restriction enzyme cutting site, detection is simple and expedient. Unfortunately, however, this occurs infrequently among CF-causing mutations, necessitating more elaborate techniques. Although these procedures all involve use of the polymerase chain reaction (PCR) (10) , approaches for detection can vary greatly, from allele-specific oligonucleotides (3), allele-specific amplification (11) , and high-resolution gel electrophoresis of the F5O8 3-bp deletion (12) , to sequence analysis (13).
Haliassos et al. (14) reported the use of PCR-mediated site-directed mutagenesis (PSM) as a means of transforming any alteration in DNA sequence into an allelespecific restriction enzyme recognition site. This is accomplished by designing a PCR primer with a singlebase mismatch that abuts the mutation under study. Amplification gives rise to a site-specific alteration in the DNA sequence of the product, which can subsequently be restriction-digested and electrophoresed to easily resolve alleles.
We have applied this methodology to detecting the zF508 deletion mutation, obviating the need for radioisotopes or rigorous high-resolution gel electrophoresis (15, 16) . This technique has similar utility in analyzing point mutations. Here we report a rapid, nonisotopic method for detecting not only the LF508 deletion but two other relatively common CF-causing mutations as well. These procedures, combined with analysis of two mutations that naturally alter restriction sites, give a facile protocol for the detection of five mutations.
MaterIals and Methods
Genomic DNA was extracted from peripheral blood leukocytes (17) . Extracted DNA was amplified by using the primers described in Figure 1 
Results
The polyacrylamide gel in Figure 3 The G551D mutation creates an Mbol restriction site without requiring PSM techniques. The 425-bp amplification product from the wild-type allele remains uncut (lane 9), whereas the mutant allele produces two fragments, 243 and 182 bp (lane 10) (6). Missense mutation N1303K is analyzed as demonstrated in lanes 6 and 7 (Figure 3, right) . After amplification of 290 bp, the sample is digested with BstN 
Discussion
We have demonstrated that PCR-mediated, site-directed mutagenesis has the capacity to expediently detect three of the more prevalent mutations that cause cystic fibrosis. The technique has proven equally capable of detecting point mutations as well as the 3-bp deletion of SF508. Combining this approach with analysis of mutations that naturally alter restriction sites allows for the detection of five different defects. The cost-effectiveness of CF carrier screening is an additional consideration. The simplicity of PSM methodology will eliminate the many collateral costs associated with radioisotopic approaches and the judgment calls often necessitated by variations in allele-specific oligonucleotide dot-blot intensity. High-resolution gel electrophoresis is well-suited to the detection of small deletions, but is incapable of detecting the multitude of point mutations that cause CF, and direct sequence analysis is prohibitively expensive. The high success rate and low ambiguity of results of PSM will reduce expenses associated with test repetition. Test affordability should improve dramatically, to the extent multiple analyses can be performed simultaneously, i.e., multiplexing (21) . To a greater or lesser degree, multiplexing may be implemented not only at the stage of amplification but also for restriction digestion and electrophoresis.
Lastly, the cost of a CF screening test potentially should drop as test volume increases. Economies of scale due to the high frequency of carriers are important considerations. Use of automated analyzers could further reduce test cost.
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